Ajai Chari, MD, on the MonumenTAL-1, MajesTEC-1 Trials

By Blood Cancer Talks - Last Updated: August 15, 2023

In this episode of “Blood Cancer Talks,” the hosts discuss the latest updates on bispecific antibodies in multiple myeloma with Ajai Chari, MD, of the Icahn School of Medicine at Mount Sinai.

They discuss data on teclistamab from the MajesTEC-1 trial, as well as key findings from the MonumenTAL-1 trial of talquetamab in multiple myeloma. Dr. Chari and the hosts also discuss a phase I trial of fixed-duration cevostamab, as well as a phase I trial of ABBV-383, and data on infections with different bispecific antibodies in multiple myeloma.

What are the Risk Factors, Treatment Options for Essential Thrombocythemia?

Dr. Samer Al Hadidi Discusses CAR-T MM Data Presented at the FDA ODAC Meeting

Ayalew Tefferi, MD, on Career Development as a Clinician-Investigator

Angela Dispenzieri, MD, on Managing Newly Diagnosed AL Amyloidosis

ASH 2023 Myeloid Recap With Anand Patel, MD

Editorial Board

Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine

Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center

Elias Jabbour, MDExecutive Editor | DB Lane Cancer Research Fund Distinguished Professor in Leukemia Research, MD Anderson Cancer Center

Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University

Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center

Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch

Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer

Ajai Chari, MD, on the MonumenTAL-1, MajesTEC-1 Trials

Related